Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1

Regulatory Peptides

Volumn 118, Issue 1-2, 2004, Pages 89-97

  Nauck, Michael A ^a,b,c   Walberg, Jörg ^b   Vethacke, Arndt ^a,b   El Ouaghlidi, Andrea ^c   Senkal, Metin ^d   Holst, Jens J ^e   Gallwitz, J Baptist ^b   Schmidt, Wolfgang E ^b   Schmiegel, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^d ST JOSEF HOSPITAL   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gastric inhibitory polypeptide (GIP); Glucagon; Glucagon like peptide (GLP 1); Gut factors; Incretin effect; Insulinotropic hormones; Parenteral nutrition

Indexed keywords

AMINO ACID; C PEPTIDE; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HORMONE DERIVATIVE; HYPERGLYCEMIC AGENT; LIPID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TOTAL PARENTERAL NUTRITION;

EID: 0842281595     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2003.11.003     Document Type: Article

References (28)

1. Creutzfeldt W. The incretin concept today. Diabetologia. 16:1979;75-85.
2. Creutzfeldt W., Nauck M. Gut hormones and diabetes mellitus. Diabetes/Metab. Rev. 8:1992;149-177.
3. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet. 2:1987;1300-1304.
4. Nauck M.A., Bartels E., Ørskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76:1993;912-917.
5. Ørskov C., Rabenhøj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes. 43:1994;535-539.
6. Ørskov C., Wettergren A., Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 31:1996;665-670.
7. Unger R.H., Eisentraut A.M. Entero-insular axis. Arch. Intern. Med. 123:1969;261-266.
8. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R. et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63:1986;492-498.
9. Nauck M., Stöckmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia. 29:1986;46-54.
10. Tillil H., Shapiro E.T., Miller A., Karrison T., Frank B.H., Galloway J.A.et al. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am. J. Physiol. Endocrinol. Metab. 254:1988;E349-E357.
11. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L.et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2:1996;1254-1258.
12. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y.et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;14843-14847.
13. Knapke C.M., Owens J.P., Mirtallo J.M. Management of glucose abnormalities in patients receiving total parenteral nutrition. Clin. Pharm. 8:1989;136-144.
14. Watters J.M., Kirkpatrick S.M., Hopbach D., Norris S.B. Aging exaggerates the blood glucose response to total parenteral nutrition. Can. J. Surg. 39:1996;481-485.
15. McMahon M.M. Management of hyperglycemia in hospitalized patients receiving parenteral nutrition. Nutr. Clin. Prac. 12:1997;35-38.
16. Nauck M.A., Heimesaat M.M., Ørskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91:1993;301-307.
17. Nauck M.A., Wallberg J., Vethacke A., Holst J.J., Senkal M., Gallwitz B. Reduction in hyperglycaemia by intravenous GLP-1 in patients under parenteral nutrition (abstract). Diabetologia. 45(Suppl. 1):2002;A215-A216.
18. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R. et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87:2002;1239-1246.
19. Holst J.J. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem. J. 207:1982;381-388.
20. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Host J.J. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes. 44:1995;1126-1131.
21. Grandt D., Sieburg B., Sievert J., Schimiczek M., Becker U., Holtmann D. Is GLP-1 (9-36)amide an endogenous antagonist at GLP-1 receptors? (abstract). Digestion. 55:1994;302.
22. Nauck M.A., Kleine N., Ørskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;741-744.
23. Rachman J., Gribble F.M., Levy J.C., Turner R.C. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia. 40:1997;205-211.
24. van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M.et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345:2001;1359-1367.
25. Qualmann C., Nauck M.A., Holst J.J., Ørskov C., Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol. 32:1995;13-16.
26. Vilsbøll T., Krarup T., Madsbad S., Holst J.J. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet. Med. 18:2001;144-149.
27. Ritzel R., Ørskov C., Holst J.J., Nauck M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia. 38:1995;720-725.
28. Nauck M.A., Wollschläger D., Werner J., Holst J.J., Ørskov C., Creutzfeldt W.et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 39:1996;1546-1553.